The first Stryker basistrabral nerve ablation system is directed to the basistrabral nerve to provide chronic vertebrogenic lumbar pain*.
Portage, Mich., May 19, 2025 / PRNewswire / – Stryker (NYSE: SYK), a world leader in medical technologies, announced that his Optablized Basivertebral nerve ablation system. Optablate BVNA is used in a minimally invasive directed procedure that provides relief of vertebrogenic pain † long duration1. The addition of Optablate BVN to Stryker’s pain portfolio expands its advanced pain therapy solutions for patients and is an intersection of its two central skills: radiofrequency ablation technology and vertebral access.
“We often see patients with chronic low back pain who have tried multiple treatments (physical therapy, injections, medications) without durable relief,” said Dr. Jad Khalil, surgeon of the backbone of Michigan’s orthopedic surgeons. “BVNA is a minimally invasive and innovative procedure that is directed to a key source of this pain, particularly in patients with specific magnetic resonance findings. Before BVNA, the options for lasting relief were limited. For many, it offers a significant improvement and can help avoid more aggressive treatments such as surgery.”
The key characteristics of the system include:
Achieve at least one 1 cm lesion in 7 minutes2 2 Obulable and dynamic curved introducer for directed microinfusion technology2, which maintains the hydrated zone, reducing impedance errors and avoiding the 10th -century caliber access tools.
“We have a long history in radiofrequency ablation, and we are relentlessly committed to offering innovative approaches to protect and promote the quality of life,” said Kristen Berg, vice president and general manager of the Stryker column column business. “Our legacy that provides solutions to reduce pain now continues with Optablate BVN, addressing the unattended population that suffers from chronic vertebrogenic low back pain.”
Stryker’s interventionist column will enter Optablate BVN as part of its pain portfolio at the annual meeting of the American Pain and Neuroscience Society (ASPN), from July 17 to 20, in Miami, fl. (Booth #154).
For questions, click here.
About Stryker
Stryker is a world leader in medical technologies and, together with its customers, we are driven to improve medical care. We offer innovative products and services in Medsurg, Neurotecnology and Orthopedics that help improve the results of patients and medical care. Together with our clients worldwide, we hit more than 150 million patients annually. More information is available at www.stryker.com.
Media contact
Beth Sizemore
Senior Communications Director
Beth.sizeemore@stryker.com
*Chronic lower back pain for at least six months that has not responded to at least six months of conservative care
† The evidence shows that patients treated with BVNA had sustained benefits in pain and function for up to 5 years
References
Fischgrund JS, Rhyne A, Macadaeg K, Moore G, Kamrava E, Yeung C, Truumees E, Schaufele M, Yuan P, Depalma M, Anderson DG, Buxton D, Reynolds J, Sikorsky M. Long results of the finishes after the results of the ends. Prospective study of multiple multiple centers controlled with randomized double blind. EUR Spine J. August 2020; 29 (8): 1925-1934. DOI: 10,1007/S00586-020-06448-X. EPUB 2020 May 25. PMID: 32451777. Stryker data in the file.
Stryker source
